Close menu




December 1st, 2020 | 09:32 CET

SAF-Holland, ElringKlinger, Almonty: cyclical for the year-end rallye

  • Investments
Photo credits: Almonty Industries

Prices are picking up once again: Vaccination hopes and the recovery of the global economy are boosting cyclical stocks, in particular, such as the automotive industry. However, base metals are also considered a good bet in times of economic upswing. But one after the other. The shares of SAF-Holland, the commercial vehicle and camping equipment supplier, rose by more than 40% on a one-year horizon. In the past few days, it still grew by more than 7% despite a minor consolidation. While the stock was still considered a beneficiary of the trend toward camping trips after the initial lockdown, the hard facts are now providing price fantasy. When the economy is booming, commercial vehicles will be needed again, according to the market.

time to read: 2 minutes | Author: Nico Popp
ISIN: CA0203981034 , DE000SAFH001 , DE0007856023

Table of contents:


    SAF-Holland and the advance praise

    SAF-Holland presented weak figures for the first half of the year, losing ground in all regions and across all business units, particularly in the wake of the pandemic. However, necessity is the mother of invention: The Company cut costs in sales and administration and made diligent savings. Nevertheless, the outlook remains subdued.

    SAF-Holland's shares are one of those cyclical stocks that are not yet really on track operationally. The price gains on the market are mostly early praise. The value may be interesting for gamblers, but those who are looking for substance are better to wait a little longer.

    ElringKlinger: 75% in one month

    The ElringKlinger share is likely to be even more in the focus of speculative investors. The specialist for cylinder-head gaskets and other parts relating to engines, transmissions and exhaust systems, is the epitome of the German supplier: its products are of a high standard and rightly in demand worldwide. However, classic engines are also a thing of the past. For this reason, too, ElringKlinger's shares were worth just EUR 3.80 in mid-March. But these times are over: Today, the share is quoted at around EUR 13.

    Last month alone, the share price rose by a breathtaking 75%. But how long has this trend been going well? With share price rallies of this kind, the principle quickly applies: "The last one bites the dust." Hardboiled gamblers should secure positions and continue to observe the situation on the market. If the mood remains rosy, even automotive suppliers can be good for a few percent.

    Almonty represents tungsten outside China

    One share that is also related to the automotive industry in a broader sense is that of the tungsten producer Almonty. The Company operates two tungsten mines in Spain and Portugal which is a ray of hope given the market dominance of China. China supplies around 80% of the world's tungsten production. The industrial metal is used, for example, in filaments in car windows, where it ensures that these can be heated and freed from ice. Tungsten also plays a role wherever corrosion protection is essential, for example, in chemical plants. Furthermore, tungsten in alloys ensures that these become heat-resistant. Tungsten is therefore also used in engines.

    In addition to the two existing mines in Southern Europe, Almonty has already begun building its mine in South Korea. Once complete, 30% of non-Chinese tungsten production will be extracted from here. Production at the Sangdong mine is scheduled to start in 2022. Almonty is collaborating with Deutsche Rohstoff AG and intends to advance the project rapidly. The preliminary work is currently ensuring that Almonty is in the red, but this is likely to be temporary. The market is presently interpreting the situation similarly: the share has bottomed out in the range of EUR 0.40.

    Base metals attractive looking to 2021

    Given the dizzying heights to which cyclical stocks such as automotive suppliers have risen, Almonty's stock currently seems anything but overbought. Although Canadian mining stocks are often under pressure in December in the wake of tax-driven sales, base metals stocks could offer opportunities in a friendly market environment looking ahead to 2021.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read